PharmaVOICE - 
Nov./Dec. 2018
Purchase Issue
In Every Issue
Letter from the Editor
The year ahead… As we come to the end of [...]
By

Taren Grom, Editor

Upfront
Johnson & Johnson Announces 10-year Initiative to Help End Tuberculosis [...]
By

PharmaVOICE Staff

HealthTech
Nanomedicine Zeros In On Triple Negative Breast Cancer Cells Trend [...]
By
Last Word
In Her Shoes: Understanding the Female Patient Experience Elizabeth Bolgiano, [...]
By

Elizabeth Bolgiano, Executive VP, Chief Human Resources Officer, AMAG Pharmaceuticals

On The Cover

2019 Trend Tracking
In this special 2019 Year in Preview issue, more than 100 PharmaVOICE thought leaders address 10 trends that are expected to be part of the changing landscape in the year ahead. These areas of focus cover a variety of disparate topics that range from molecule to market in keeping with our publishing focus and philosophy. [...]
By

Taren Grom, Editor

Features

Looking Forward To
AI Adoption Richard Davies VP, Solution Expert, CluePoints The application of artificial intelligence and machine learning within the R&D process to guide disparate stakeholders through the planning and execution of clinical trials through targeted risk management is both a current capability and an evolving trend. This helps support the industry as it moves to implement [...]
By

Taren Grom, Editor

Trend: 3D and Bioprinting
The bioprinting field continues to grow and mature. With the evolution of the technology, experts believe even broader applications are on the horizon, providing patients with fully functioning cells — and even organs — that have been created through bioprinting processes. “All of us can envision a day when bioprinting technologies will allow us to [...]
By

Denise Myshko

Trend: Advanced Diagnostics and Precision Medicine
Healthcare is moving increasingly toward personalized approaches — tailoring treatment based on each patient’s unique disease. Precision medicine is well-established in oncology, with many cancers now characterized by their unique genomic alterations. In the past few years, the Food and Drug Administration has approved several treatments based on an individual’s genetic makeup or genetic variants [...]
By

Denise Myshko

Trend: Creating Shared Value
Shared value was first introduced by Michael Porter and Marc Kramer in their Harvard Business Review article in 2011. Since then, multiple industries have assessed how to implement shared value into their business practices. In other industries, companies need to work hard to find a public good that they can commit to working toward, however, [...]
By

Taren Grom, Editor

Trend: Genetic Testing and Data Privacy and Ownership
Genetic testing is a booming market. According to reports, as of April 2018 more than 15 million people had taken direct-to-consumer genetic tests, and with prices for autosomal DNA tests now costing less than 0, they have become very accessible. Companies such as 23andMe, Ancestry.com, and MyHeritage are making it easy for consumers to test [...]
By

Kim Ribbink

Trend: The Gig Economy
The rise of the gig economy is empowering workers to maximize their freedom and choose journeys over jobs. According to Morgan Stanley, within 10 years, freelance workers may represent more than 50% of the U.S. working population — leaving big questions as to what are the implications for corporations and corporate cultures. Shifting demographics, digitalization, [...]
By

Taren Grom, Editor

Trend: Innovative Product Launches
Increasing complexity in the market and pressure on managing costs already create many challenges when it comes to new drug launches. Add to that the intricacies of innovative and combination drugs and the speed at which they need to launch, and challenges multiply. However, this shifting environment also presents opportunities for companies that proactively adapt [...]
By

Robin Robinson

Trend: Multistakeholder Commercial Models
In the coming years, pharma will mobilize around engaging and accommodating a multitude of stakeholders to generate a competitive advantage. Long gone are the days of targeting healthcare providers as the entire commercial strategy. Simplicity in commercialization no longer exists and has been replaced with a complex multistakeholder model involving physicians, of course, but also [...]
By

Robin Robinson

Trend: Rare Disease Innovation
It’s been almost 120 years since the word gene was coined. Today, researchers are well on their way to manipulating genes to treat diseases. With only about 400 approved treatments for more than 7,000 rare diseases — 80% of which are caused by gene mutations — scientific advances are enabling gene manipulation for both prevention [...]
By

Taren Grom, Editor

Trend: R&D Modeling and Simulation
The Food and Drug Administration for several years has been advocating for the use of computer modeling and simulation as a way to accelerate access to new therapies. First proposed by the agency in 2011 as part of its Critical Path Initiative, modeling and simulation are gaining traction, with the global biosimulation market expected to [...]
By

Denise Myshko

Trend: Voice Assistants
Alexa, how will voice assistants impact the pharmaceutical commercial landscape in the next five years? Alexa is “not sure about that,” but our experts have the answers as smart speakers and voice technology begin to penetrate not only healthcare, but the pharma commercialization process as well. Juniper Research predicts there will be 275 million voice [...]
By

Robin Robinson

SHOWCASE: eSolutions: Changing the Face of Patient Empowerment
With so many new players entering the realm of eSolutions to drive patient engagement and patient empowerment, life-sciences companies ignore digital innovation at their peril. What exactly are eSolutions in the context of healthcare delivery? Over the past few years, eSolutions have become more widely deployed in clinical trials, for example, to collect patient reported [...]
By

PharmaVOICE Staff

How Pharma Can Benefit From the EHR
The digital age has been making waves since the late 1900s and the electronic health record (EHR) industry is one small piece in a vast pool of digital channels available for pharmaceutical companies through which to message their brands. The EHR, or EMR (electronic medical record), has been an important, useful vehicle used to deliver [...]
By

Kaitlyn Clark, Associate Digital Strategist, and Anika Patel, Digital Strategist, EHR, Ogilvy Health

If You Build It, Will They Come
A colleague of mine here at the agency shared a fascinating article in our Slack channel with this compelling quote: “I did not go to medical school to sit on my butt for four to six hours a day doing data entry in a computer…”1 I feel for this doctor. I recall the time when [...]
By

Rico Cipriaso, VP, Engagement Strategy, Ogilvy Health

Digital Media Gets Social: The Five W’s
While traditionally slow to adopt new innovations across many sectors, pharmaceutical and healthcare organizations have become more immersed in mainstream culture and have evolved their promotional plans accordingly. Following the societal trend of digital dependency, industry spend towards communicating with patients and prescribers is increasing. A recent study by eMarketer suggests that pharma and healthcare [...]
By

Elizabeth Hefner, VP, Marketing & Member Services, Skipta

Avoid Enrollment Pitfalls by Engaging with Best-Fit Sites
Perhaps the single most important consideration in selecting a site is whether it can make its enrollment. Many don’t; in fact, 20% to 25% of all clinical studies close because they fail to meet enrollment targets.1 For decades, sponsors have found their “best fit” sites and returned to them for future studies. But in the [...]
By

Seth Nelson, VP of Operations, WCG ThreeWire

Speak Out
Looking to Simplify Your Safety Notifications Process? Consider a Cross-Trial SaaS Solution Why new centralized SaaS solutions make more sense than ever before A traffic-light is out of service during rush hour in a busy city intersection. To prevent accidents, a police officer is there directing traffic. Suddenly, three more show up, each directing traffic [...]
By

Brian Fisher, President, Trial Management at DrugDev

FEEDBACK